[ad_1]
TOKYO, March 28, 2019 / PRNewswire / – The Innovative Health Technologies Fund (GHIT) announced today the appointment of Catherine Ohura as Chief Executive Officer and Executive Director of the organization. Ohura brings in-depth expertise and invaluable experience in the areas of research and development and commercial activities. In the R & D function, Ohura worked in the areas of clinical operations, regulatory affairs, quality badurance, project management, financial / resource management, portfolio management and creation / management of governance.
"The entire board of directors of GHIT and I are delighted to welcome Catherine Ohura, a highly skilled and experienced leader of the pharmaceutical industry," said Hiroki Nakatani, Chairman of the board of the GHIT Fund and Managing Director. "Ohura shares with us our vision and mission and we believe that it will advance global health innovation for neglected patients around the world by leading and collaborating with the team. direction of GHIT. "
"She has a forward-looking vision and strong pbadion that is critical to solving global health issues, and I'm confident that under her leadership, GHIT will further accelerate product development by: From Japan science and innovation partnering with global entities to save millions of people suffering from neglected diseases, "said BT Slingsby, founding CEO of the GHIT Fund.
Prior to her appointment as CEO and Executive Director of GHIT, Ohura served as Managing Director and Head of Commercial Operations and Customer Experience in Japan at Bristol-Myers Squibb (BMS) K.K. (located in Japan). She has also been a member of senior management and Senior Director, Regional R & D Operations (in charge of JapanR & D in China) at BMS K.K. At BMS (USA), she held the position of General Manager / Global Head of the BMS Women's Network (B-NOW). In this role as a revolutionary leader in the sector, she led BMS 'global business performance by promoting a more diversified and broadly inclusive business strategy. Prior to working at BMS, Ohura worked in a Japanese pharmaceutical company for clinical development, regulatory affairs, quality badurance, pharmacovigilance and project management.
Ohura was born and raised in Japan and studied and worked in both Japan and United States. She holds a Bachelor's degree in Chemistry, Mathematics and Business from the University of Denver, and a master's degree in regulatory affairs and quality badurance from University of the Temple School of Pharmacy. She completed everything except her thesis in the doctoral program in project management at Capella University and is certified PMP (Project Management Professional).
"I am truly honored to join GHIT as CEO and I am delighted to work with its Governors, product development partners and global stakeholders in global health research and development and access. to this one, "said Ohura. "Throughout my career in the pharmaceutical industry, I've always believed in the power of intersectoral partnerships as a key to advancing science and innovation. I am delighted to lead GHIT in its next phase and advance the global partnerships global entities.I will commit to delivering the necessary, affordable products in the coming years and to those who need it most. "
Quotes from GHIT Financial Partners
Isao Teshirogi, Shionogi & Co., Ltd., President and Chief Executive Officer (President, Federation of Product Manufacturers Associations)a saucepan)
"Ohura's experience and expertise in the pharmaceutical industry will play a critical role in the success of GHIT's Phase 2 strategic plan, and it will inspire great confidence and will certainly keep GHIT on the track." the achievement of its ambitious goal of providing innovative products that can be needed. "
Trevor Mundel, President of Global Health, Bill & Melinda Gates Foundation
"Catherine Ohura will further enhance the value of this international public-private partnership between the for-profit philanthropic triad and the government that differentiates GHIT from many other organizations."
Jeremy Farrar, Director, Wellcome
"As the new CEO and CEO of GHIT, Catherine Ohura will lead health innovation through global collaboration, and her international journey will be central to the transition. Japan and the global community to encourage innovations and access for neglected patients around the world. "
Hideo Suzuki, Ambbadador, Deputy Minister of Global Affairs / Director General for Global Issues, Department of Foreign Affairs
"We believe that Ms. Ohura's leadership will advance the mission of GHIT, which plays a vital role in the implementation of the central pillars of From Japan foreign policy, including human security and universal health coverage. We also hope that it will accelerate the development of neglected patient products in low- and middle-income countries by using From Japan advanced technology and innovation. "
Chieko IkedaDeputy Prime Minister for Global Health, Minister's Office, Department of Health, Labor and Welfare
"Under Ohura's leadership, we are confident that GHIT will continue to harness the scientific and technological strength of our country to fulfill From Japan the responsibility to work with global stakeholders to eliminate some of the neglected diseases around the world. "
About the GHIT fund
The first of its kind in Japan, the GHIT Fund is an international public-private partnership between the Government of Japan, several pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome and the United Nations Development Program (UNDP). The GHIT Fund invests and manages a portfolio of development partnerships focused on neglected diseases, such as malaria, tuberculosis and neglected tropical diseases, that affect the world's poorest populations. The GHIT Fund mobilizes Japanese pharmaceutical companies, universities and research organizations to engage in the creation of new medicines, vaccines and diagnostics. For more information, please visit https://www.ghitfund.org.
SOURCE Innovative Health Technology Fund (GHIT)
Related Links
https://www.ghitfund.org
Source link
